Publications by authors named "Shuang-Li Yang"
Corrigendum: Dapagliflozin Attenuates Hyperglycemia Related Osteoporosis in ZDF Rats by Alleviating Hypercalciuria.
Front Endocrinol (Lausanne)
September 2020
[This corrects the article DOI: 10.3389/fendo.2019.
View Article and Find Full Text PDFDapagliflozin Attenuates Hyperglycemia Related Osteoporosis in ZDF Rats by Alleviating Hypercalciuria.
Front Endocrinol (Lausanne)
November 2019
Recent studies showed that in patients with type 2 diabetes mellitus (T2DM), Sodium-dependent glucose transporters 2 inhibitor (SGLT2I) may cause potential adverse effects on the skeleton such as increasing the risk of fracture. This risk is possibly mediated by effects induced by all SGLT2I class drugs, but whether Dapagliflozin aggravates osteoporosis in patients with T2DM remains controversial. Therefore, we designed this study to explore how Dapagliflozin affects the metabolism and the quality of bone in T2DM animal models.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how angiotensin II type 1 receptor blocker (ARB), particularly irbesartan, can counteract bone damage in diabetes caused by advanced glycation end products (AGEs).
- Through a 12-week intervention in db/db mice, results showed significant improvements in bone microarchitecture and biomechanical strength, indicating that irbesartan helps protect bone health.
- The research concludes that irbesartan potentially shields against AGEs-induced oxidative stress and cell damage in osteoblasts, suggesting a new therapeutic approach for diabetes-related osteoporosis.
Background: Pneumocystis pneumonia (PCP) is an emerging infectious disease in immunocompromised hosts. However, the clinical characteristics of these patients are poorly understood in mainland China.
Methods: We performed a retrospective study of PCP from 2008 to 2012.